Expert Perspectives on Fixed Duration Therapy with Venetoclax + Obinutuzumab

Opinion
Video

A panel of experts discuss the role of fixed duration therapy with venetoclax and obinutuzumab, outlining their general approach for patient selection.

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
Symposiums and regional meetings may expand knowledge of how to adopt novel CAR T-cell therapies and bispecific antibodies, said Suman Kambhampati, MD.
A 2-way communication between providers and patients may help facilitate dose modifications to help better manage adverse effects.
Treatment with AML depends on a variety of factors, including stage of treatment, transplant eligibility, and mutational status.
Related Content
What Path to Approval Has Dasatinib Taken in CML/ALL?

What Path to Approval Has Dasatinib Taken in CML/ALL?

Ariana Pelosci
October 27th 2025
Article

Over the past 4 years, the FDA has accepted a number of NDA submissions for dasatinib, but it has yet to receive approval in CML/ALL.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

The FDA has set a Prescription Drug User Fee Act date of June 18, 2026, for approving this formulation of nilotinib in chronic myeloid leukemia.

FDA Accepts NDA for New Nilotinib Formulation in CML

Russ Conroy
October 23rd 2025
Article

The FDA has set a Prescription Drug User Fee Act date of June 18, 2026, for approving this formulation of nilotinib in chronic myeloid leukemia.

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

FDA Issues CRL for Dasatinib in CML/ALL

FDA Issues CRL for Dasatinib in CML/ALL

Ariana Pelosci
October 20th 2025
Article

Based on the Good Manufacturing Practice observations, the FDA has given a complete response letter for dasatinib for patients with CML/ALL.

Two hematologic oncologists defined rare lymphomas and highlighted challenges and recent developments associated with these disease types.

Outlining Considerations for the Rare Lymphoma Treatment Paradigm

Roman Fabbricatore
October 17th 2025
Article

Two hematologic oncologists defined rare lymphomas and highlighted challenges and recent developments associated with these disease types.